By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Synthon Pharmaceuticals, Ltd. 

6330 Quadrangle Drive, Suite 305

Chapel Hill  North Carolina  27514  U.S.A.
Phone: 919-493-6006 Fax: 919-493-6104


SEARCH JOBS


Industry
Pharmaceutical






Company News
Synthon Pharmaceuticals’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC 4/2/2014 9:31:05 AM
Synthon Pharmaceuticals Announces Successful Outcome Of The Phase 3 GATE Study With Its Generic Glatiramer Acetate 3/27/2014 9:25:12 AM
Synthon Pharmaceuticals Enters Into Global License Agreement With Amgen (AMGN) and Watson Pharmaceuticals, Inc. (WPI) for Biosimilar Trastuzumab 7/18/2012 9:18:09 AM
Synthon Pharmaceuticals Appoints Paul Roos as Chief Financial Officer 5/7/2012 10:20:40 AM
Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab 3/22/2012 1:30:10 PM
Perrigo Company (PRGO) and its Partner Synthon Pharmaceuticals Launch Levocetirizine Solution - Generic Equivalent to Xyzal(R) Oral Solution 11/8/2011 6:02:57 AM
Perrigo Co. (PRGO)'s Partner Synthon Pharmaceuticals Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal(R) Oral Solution 5/18/2011 9:01:45 AM
Breckenridge Pharmaceutical, Inc. and Synthon Pharmaceuticals Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation With Takeda Pharmaceutical Co. Ltd. (TKDG.DE) 5/16/2011 9:58:13 AM
Perrigo Company (PRGO) Confirms That its Partner Synthon Pharmaceuticals Has Filed for Generic Version of Xyzal(R) 6/24/2009 10:34:29 AM
Perrigo Company (PRGO) Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon Pharmaceuticals 9/8/2008 6:49:58 AM
12
//-->